QUIA PHARMA AB (FRA:99B0) EBITDA Margin %: 0.00% (As of Jun. 2025)


What is QUIA PHARMA AB EBITDA Margin %?

QUIA PHARMA AB FRA:99B0 EBITDA Margin % is 0.00% as of Jun. 2025. The stock has 3 warning signs investors should review.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. QUIA PHARMA AB's EBITDA for the six months ended in Jun. 2025 was €-0.31 Mil. QUIA PHARMA AB's Revenue for the six months ended in Jun. 2025 was €0.00 Mil. Therefore, QUIA PHARMA AB's EBITDA margin for the quarter that ended in Jun. 2025 was 0.00%.

QUIA PHARMA AB  (FRA:99B0) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

QUIA PHARMA AB EBITDA Margin % Related Terms

QUIA PHARMA AB EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for QUIA PHARMA AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

QUIA PHARMA AB EBITDA Margin % Chart

QUIA PHARMA AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,271.04 0.00 0.00 0.00 0.00

QUIA PHARMA AB Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:99B0 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, QUIA PHARMA AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

QUIA PHARMA AB EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, QUIA PHARMA AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where QUIA PHARMA AB's EBITDA Margin % falls into.


QUIA PHARMA AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

QUIA PHARMA AB's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-0.844/0
= %

QUIA PHARMA AB's EBITDA Margin % for the quarter that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-0.313/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
QUIA PHARMA AB (FRA:99B0) has a EBITDA Margin % of 0.00% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on QUIA PHARMA AB and its competitors.
Is QUIA PHARMA AB's EBITDA Margin % too high?
QUIA PHARMA AB's current EBITDA Margin % is 0.00%.
How does QUIA PHARMA AB's EBITDA Margin % compare to VRTX and REGN?
QUIA PHARMA AB's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on QUIA PHARMA AB and its competitors. QUIA PHARMA AB's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QUIA PHARMA AB stock overvalued right now?
QUIA PHARMA AB (FRA:99B0) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For QUIA PHARMA AB (FRA:99B0), the current EBITDA Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

QUIA PHARMA AB Business Description

Address Virdings Alle 32 B, Uppsala, SWE, 754 50
QUIA PHARMA AB is a development company for pharmaceuticals based on a patented drug delivery platform, Uni-Qleaver. The company develops improved and patentable forms of drugs under development or already approved by pharmaceutical authorities. These refined and enhanced forms of medicine are based on the Company's exceptional and patented technology platform. In addition to this, the Company offers multinational sales of omega-3, astaxin and collagen through Amazon.